Talphera, Inc. (Nasdaq: TLPH), a specialty pharmaceutical company, has announced a securities purchase agreement with CorMedix Inc. and certain institutional investors. The agreement involves the sale and issuance of common stock and pre-funded warrants for potential proceeds of up to $29 million. In the initial closing, Talphera will issue over 25 million shares of common stock and nearly 6 million pre-funded warrants. An additional tranche of $12 million in shares and warrants is contingent upon the achievement of specific milestones in the NEPHRO CRRT clinical study and the company's stock trading at a minimum agreed price. CorMedix will make a strategic investment, with the institutional investors purchasing at market prices. The deal is structured as a private placement under the Securities Act of 1933.